USA-based Ardea Biosciences says data from a preclinical study of RDEA119, its lead mitogen-activated ERK kinase inhibitor, showed it to be a promising investigational therapy for inflammatory diseases.
Findings presented at the American College of Gastroenterology annual meeting in Orlando, Florida, demonstrate that oral administration of RDEA119 was shown to significantly reduce damage to colonic tissue and disease activity in dextran sulfate sodium-induced chronic colitic mice. The beneficial effect of RDEA119 exceeded that of Remicade (infliximab), the current standard-of-care for the treatment of ulcerative colitis, the firm noted.
"Blocking the MEK1/2 pathway appears to be a promising strategy for treating inflammatory disease, for which a significant unmet medical need still exists," said Barry Quart, Ardea's chief executive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze